Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × OTHER × elacestrant × Clear all

Phase

Phase 2 12 Phase 3 2 Phase EARLY_PHASE1 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

INDUSTRY 6 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Cyclophosphamide 248 Radiotherapy 172 pembrolizumab 153 Carboplatin 147 Gemcitabine 138 Nivolumab 135 Paclitaxel 129 Dexamethasone 117 Cisplatin 117 fludarabine 112 Rituximab 102 Lenalidomide 102 Bevacizumab 98 Docetaxel 97 Capecitabine 96 fludarabine phosphate 91 Temozolomide 88 Cytarabine 88 Oxaliplatin 86 Etoposide 82 Filgrastim 76 Irinotecan 73 Doxorubicin 73 venetoclax 69 Peripheral Blood Stem Cell Transplantation 68 Fluorouracil 67 Melphalan 66 Everolimus 66 Radiosurgery 64 Bortezomib 64

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07198724 2026-04-09

ERADICATE

Dana-Farber Cancer Institute

Phase 1/2 Recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡